Australia's Kazia Therapeutics jumps as study begins for brain tumour medication

Kazia Therapeutics

15/06/2021 03:54

** Kazia Therapeutics  KZA.AX  shares rise as much as 13% to
A$1.48, their highest since April 20
    ** Cancer drug maker launches phase 2 clinical study on the
use of its new drug paxalisib for an aggressive form of brain
tumour  urn:newsml:reuters.com:*:nASN001BKB
    ** Stock sees its biggest single-day jump since March-end in
its second consecutive session of gains 
    ** Nearly 2 mln shares change hands, 1.6 times the 30-day
average

 ((rushil.dutta@thomsonreuters.com))